Tulane University Health Sciences
Department of Pathology and Laboratory Medicine
1430 Tulane Avenue SL-79
New Orleans, Louisiana
Dr. Han’s research is focused on studying the cellular and molecular pathways leading to liver carcinogenesis and exploring novel strategies for therapeutic interventions. A variety of cell culture and animal models are being utilized to study the biological roles of several key enzymes in the prostaglandin biosynthetic pathway, including cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH), in liver carcinogenesis and their interactions with other key molecules pivotal for hepatobiliary cell growth and carcinogenesis. And all studies are aimed to develop novel therapeutic strategies for effective prevention and treatment of human liver cancer.
Lu DD, Han C and Wu T. Microsomal prostaglading E synthease-1 (mPHES-1) promotes experimental cholangiocarcinogenesis and tumor progression through inhibition of PTEN pathway. Gastroenterology. 2011, 40 (7): 2084-94.
Han C, Bowen WC, Li GY, Demetris AJ, Michalopoulos GK and Wu T. Cytosolic phospholipase A2alpha and PPAR-gamma signaling pathway counteracts TGF-beta-mediated inhibition of primary and transformed hepatocyte growth. Hepatology, 2010, 52 (2): 644-655.
Lim K, Han C, Dai YF, Shen M and Wu T. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and COX-2. Mol. Cancer Ther. 2009 8 (11): 3046-55.
Li G, Han C, Xu L, Lim K, Isse K and Wu T. Cyclooxygenase-2 prevents Fas-induced liver injury through upregulation of epidermal growth factor receptor. Hepatology 2009 50 (3): 834-43.
Han C, Lim C, Li GY, DeFrances MC, Xu LH, Gandhi CR and Wu T. Transgenic expression of cyclooxygenase-2 in hepatocytes accelerates endotoxin-induced acute liver failure. J. Immunol. 2008, 181 (11): 8027-8035.
Han C, Lim K, Xu LH, Li GY and Wu T. Regulation of Wnt/beta-catenin pathway by cPLA2alpha-mediated PPARdelta activation. J. Cell. Biochem 2008, 105 (2): 534-545.
Han C, Bowen WC, Michalopoulos GK and Wu T. Alpha-1 adrenergic receptor transactivates signal transducer and activator of transcription-3 (Stat3) through activation of Src and epidermal growth factor receptor (EGFR) in hepatocytes. J. Cell. Physiol. 2008, 216(2): 486-97.
Lim K, Han C, Xu LH, Isse K, Demetris AJ and Wu T. COX-2-derived PGE2 activates beta-catenin in human cholangiocarcinoma cells: Evidence for inhibition of these signaling pathways by omega-3 polyunsaturated fatty acids. Cancer Res. 2008, 68(2): 553-60.
Xu LH, Han C, Lim K and Wu T. Activation of cytosolic phospholipase A2alpha through S-nitrosylation: involvement of inducible nitric oxide synthase and cyclooxygenase-2. J. Biol. Chem. 2008, 283(6): 3077-87.
Han C, Demetris AJ, Stolz D, Xu LH, Lim K and Wu T. Modulation of Stat-3 activation by the cPLA2alpha and COX-2 controlled PGE2 signaling pathway. J. Biol. Chem. 2006, 281(34): 24831-24846.
Xu LH, Han C, Lim K and Wu T. Cross-talk between PPARdelta and cPLA2alpha/COX-2/PGE2 signaling pathways in human hepatocellular carcinoma cells. Cancer Res. 2006, 66(24): 11859-68.
Han C, Michalopoulos GK, and Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/Met receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J. Cell. Physiol. 2006, 207(1): 261-270.
Xu LH, Han C and Wu T. A novel positive feedback loop between PPARdelta and PGE2 signaling pathways for human cholangiocarcinoma cell growth. J. Biol. Chem. 2006, 281(45): 33982-33996.
Han C and Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J. Biol. Chem. 2005, 280 (25): 24053-24063.
Han C, Demetris AJ, Liu Y, Shelhamer JH and Wu T. TGF-beta activates cPLA2alpha-mediated PGE2/EP1 and PPAR-gamma/Smad signaling pathways in human liver cancer cells: a novel mechanism for subversion of TGF-beta-induced mitoinhibition. J. Biol. Chem. 2004, 279 (43): 44344-44354.
Wu T, Leng J, Han C and Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells: evidence for involvement of COX-2-independent mechanisms. Mol. Cancer Ther. 2004, 3: 299-307.
Han C, Leng J, Demetris AJ and Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma cell growth: evidence for cyclooxygenase-2 independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 2004, 64: 1369-1376.
Wu T, Han C and Shelhamer JH. Involvement of p38 and p42/44 MAP kinases and protein kinase C in the interferon-gamma and interleukin-1-beta-induced phosphorylation of 85-kDa cytosolic phospholipase A2 in primary human bronchial epithelial cells. Cytokine 2004, 25(1): 11-20.
Leng J, Han C, Demetris AJ, Michalopoulos GK and Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003, 38: 756-768.
Han C, Demetris, AJ, Michalopoulos GK, Zhan Q, Shelhamer JH and Wu T. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21WAF/Cip1 pathway. Hepatology 2003, 38: 167-177
Pawliczak R, Han C, Huang XL, Demetris AJ, Shelhamer JH and Wu T. 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor-gamma activation in human lung epithelial cells. J. Biol. Chem. 2002, 277(36): 33153-33163.
Wu T, Han C, Lunz JG, Michalopoulos G, Shelhamer JH and Demetris AJ. Involvement of 85-kd cytosolic phospholipase A2 and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. Hepatology 2002, 36: 363-373.
Han C, Demetris AJ, Michalopoulos G, Shelhamer JH and Wu T. 85-kDa Cytosolic phospholipase A2 plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am. J. Physiol. (GI Liver Physiol). 2002, 282(4): G586-597.
Dept. of Pathology & Laboratory Medicine, 1430 Tulane Avenue, New Orleans, LA 70112 504-988-5224 firstname.lastname@example.org